Ann Optom Contact Lens.  2021 Sep;20(3):119-123. 10.52725/aocl.2021.20.3.119.

Cosmetic Nd:YAG Laser-assisted Maculopathy Treated with Early Anti-vascular Endothelial Growth Factor Antibody

• Ma GJ
• Park SK
• Kim M
• Park YG
• Park YH
• Kim RY

• KMID: 2532535
• DOI: http://doi.org/10.52725/aocl.2021.20.3.119

Abstract

Purpose
To report a follow up of early intravitreal anti-vascular endothelial growth factor (VEGF) antibody treatment in a patient with maculopathy after accidental exposure to a high-powered cosmetic Nd:YAG laser.
Case summary
A 36-year-old female patient visited our clinic with decreased visual acuity in the right eye after accidental exposure to a high-powered cosmetic Nd:YAG laser. The best-corrected visual acuity of the right eye was 0.1 and subretinal hemorrhage on the foveal area was observed during fundus examination. Optical coherence tomography revealed serous retinal detachment with hyperreflective disruption of the ellipsoid zone and retinal pigment epithelium-Bruch’s membrane complex. Intravitreal bevacizumab (Avastin ^® , 1.25 mg/0.05 mL; Roche Korea, Seoul, Korea) injections were performed three times. Visual acuity was unchanged at 6 months after the first visit. However, complete resolution of the subretinal hemorrhage was observed and there were no signs of secondary choroidal neovascularization or recurrence of choroidal hemorrhage.
Conclusions
Early anti-VEGF antibody treatment in a patient with subfoveal hemorrhage and choroidal rupture after high-powered cosmetic Nd:YAG laser exposure improved morphology and prevented secondary choroidal neovascularization.

Keyword

Bevacizumab; Maculopathy; Nd:YAG; Optical coherence tomography